Interleukin-1 in the treatment of cancer

Pharmacol Ther. 1995 Mar;65(3):291-302. doi: 10.1016/0163-7258(95)98595-h.


Interleukin-1 (IL-1) is a cytokine with many activities central to immune function and hematopoiesis. Many IL-1 properties can be potentially exploited in the treatment of malignancy. This review describes the toxicities and antitumor effects observed in Phase I and II trials of IL-1 in cancer patients. The immunophysiology and the induction of cytokines by IL-1 has been examined in many of the Phase I trials and has aided in understanding IL-1 effects in humans. The influence of IL-1 on granulopoiesis and thrombopoiesis when given by different regimes is also reviewed in detail.

Publication types

  • Review

MeSH terms

  • Animals
  • Bone Marrow Transplantation
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Humans
  • Interleukin-1 / therapeutic use*
  • Neoplasms / drug therapy*


  • Interleukin-1